However, in the same study, better tumor-targeting properties were obtained by radioiodination of the same Nb using [131I]IB-Mal-D-GEEEK as a prosthetic group. reported. Keywords:nanobodies, targeted radionuclide therapy, HER2 breast cancer, radiolabeling strategies, nuclear imaging == 1. Introduction == Breast cancer (BC) is the second leading cause of mortality for women worldwide [1]. BC harboring overexpression of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2) and/or amplification of the HER2/neu gene accounts for about 20% of all BCs [2]. Furthermore, HER2 expression can change during the course of the disease and can be unequally expressed across primary tumor and metastatic lesions. Excessive HER2 signaling triggers activation of downstream pathways, promoting proliferation, motility and survival rate of cancer cells, which ultimately translates into an aggressive behavior, with a higher risk of metastases and shorter overall survival CP 945598 HCl (Otenabant HCl) [3,4]. In light of its key biological role in tumorigenesis, HER2 has become an attractive target for BC diagnosis and CP 945598 HCl (Otenabant HCl) therapy. Since only a subset of BC patients has HER2-positive (HER2+) tumors, robust assessment of HER2 expression represents a critical step in selecting patients who might benefit from HER2-targeted therapies. Currently, HER2 status is determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), both requiring invasive procedures for biopsy sample collection [5]. These histopathological methods do not address the whole-tumor heterogeneity and are limited by the sampling of a site at a certain time point, producing many times false-negative or false-positive results, which further impact on the proper selection of treatments [6,7]. Moreover, these techniques are not informative about variations in HER2 levels between main HER2+BC and distant metastases [8,9,10,11]. Consequently, a more comprehensive method for the assessment of HER2 manifestation in both main tumors and distant metastasis is needed. Molecular imaging techniques using radiopharmaceuticals can be used to reduce this source of incertitude in the evaluation of HER2 manifestation. This non-invasive imaging approach has the potential to provide information about the global status of HER2 in main and distant metastatic lesions, at the same time [12]. Furthermore, this approach allows us to monitor the response to HER2-targeted therapies and to determine the individuals who become resistant [12,13,14]. The development of HER2-targeted therapies using monoclonal antibodies (mAb), such as trastuzumab and pertuzumab and tyrosine kinase inhibitors, such as lapatinib, offers significantly improved the survival of individuals with HER2+BC. However, HER2-targeted therapy remains challenging since not all individuals respond and a significant quantity of the responders eventually relapse or become resistant to the therapy [15]. Further attempts are still needed toward designing more specific and effective restorative providers for treating individuals resistant to HER2-targeted therapies. One alternate strategy is definitely targeted radionuclide therapy (TRNT) in which a tumor-specific molecule labeled having a cytotoxic radionuclide is used CP 945598 HCl (Otenabant HCl) to locally irradiate targeted tumor cells. Several HER2-targeted vehicles, such as monoclonal antibodies (mAb), antibody-based fragments (Fab), diabodies, minibodies, nanobodies (Nb) and affibodies, have been explored for HER2+BC imaging and TRNT in the past few years [16]. In particular, Nb, also referred to as single-domain antibodies or VHH molecules, are proteins based on the smallest practical fragments of weighty chain antibodies happening inCamelidae[17] with attractive features for radiolabeled imaging and TRNT applications [18]. The optimal choice of radiolabeling strategies will determine the Nb potential as imaging providers and therapeutics, that are dependent on their connection with targeted cells. With this review, we will provide a general overview of antibody-based molecular imaging, with a special focus on Nb as imaging tracers and vehicles for TRNT. Subsequently, we will CP 945598 HCl (Otenabant HCl) provide the current knowledge concerning the radiolabeling strategies of Nb and the difficulties facing the translation of Tnfrsf10b preclinic studies into the medical establishing. == 2. Nuclear Imaging and Targeted Radionuclide Therapy == Nuclear.